Matches in SemOpenAlex for { <https://semopenalex.org/work/W2568303126> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W2568303126 endingPage "S255" @default.
- W2568303126 startingPage "S254" @default.
- W2568303126 abstract "Checkpoint inhibitors such as the anti–PD-1 monoclonal antibody pembrolizumab have demonstrated antitumor activity and a manageable safety profile in several advanced malignancies. Although checkpoint inhibitors are rapidly becoming a standard-of-care therapy in multiple tumor types, the optimal treatment duration has not been established. We plan to assess outcomes in patients who completed the maximum 24 months of pembrolizumab in the phase 3 KEYNOTE-010 study (NCT01905657), in which pembrolizumab provided superior OS over docetaxel in patients with previously treated, PD-L1–expressing advanced NSCLC. 1034 patients with advanced NSCLC that progressed after ≥2 cycles of platinum-based chemotherapy (and an appropriate therapy for targetable EGFR and ALK aberrations if present) and had a PD-L1 tumor proportion score ≥1% were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg Q3W or to docetaxel 75 mg/m2 until disease progression, intolerable toxicity, physician or patient decision; the maximum duration of pembrolizumab was 24 months of uninterrupted treatment or 35 cycles, whichever was later. Response was assessed per RECIST v1.1 every 9 weeks. After completion of 24 months/35 cycles, patients continued to undergo imaging every 9 weeks; patients with subsequent disease progression were eligible for a second treatment course if they did not receive other anticancer therapy after stopping pembrolizumab. Reason late-breaking status required: As of the most recent analysis, which had a data cutoff date of March 31, 2016, and a median follow-up of 19.2 months (range, 11.7-29.7), only 3 patients in each pembrolizumab arm completed 24 months/35 cycles of treatment. At the time of the next data analysis, which is planned for September 2016, we expect ≥35 patients to have reached the 24-month/35-cycle plateau, allowing for a more robust analysis. Anticipated data: We anticipate providing the following for patients who completed 24 months/35 cycles of pembrolizumab: best overall response, ORR, time to response, and duration of response to first-course therapy; time since the last pembrolizumab dose; incidence of death and disease progression after stopping pembrolizumab; and frequency of second-course initiation." @default.
- W2568303126 created "2017-01-13" @default.
- W2568303126 creator A5001428569 @default.
- W2568303126 creator A5002019310 @default.
- W2568303126 creator A5008127215 @default.
- W2568303126 creator A5008593691 @default.
- W2568303126 creator A5018757509 @default.
- W2568303126 creator A5019037704 @default.
- W2568303126 creator A5023055777 @default.
- W2568303126 creator A5025836672 @default.
- W2568303126 creator A5040129979 @default.
- W2568303126 creator A5040900859 @default.
- W2568303126 creator A5045508144 @default.
- W2568303126 creator A5047152744 @default.
- W2568303126 creator A5047402540 @default.
- W2568303126 creator A5049735686 @default.
- W2568303126 creator A5050112931 @default.
- W2568303126 creator A5055548058 @default.
- W2568303126 creator A5059355812 @default.
- W2568303126 creator A5060287300 @default.
- W2568303126 creator A5064697305 @default.
- W2568303126 creator A5079876695 @default.
- W2568303126 creator A5080195917 @default.
- W2568303126 date "2017-01-01" @default.
- W2568303126 modified "2023-10-01" @default.
- W2568303126 title "OA03.07 KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab" @default.
- W2568303126 doi "https://doi.org/10.1016/j.jtho.2016.11.243" @default.
- W2568303126 hasPublicationYear "2017" @default.
- W2568303126 type Work @default.
- W2568303126 sameAs 2568303126 @default.
- W2568303126 citedByCount "17" @default.
- W2568303126 countsByYear W25683031262017 @default.
- W2568303126 countsByYear W25683031262018 @default.
- W2568303126 countsByYear W25683031262019 @default.
- W2568303126 countsByYear W25683031262020 @default.
- W2568303126 countsByYear W25683031262021 @default.
- W2568303126 countsByYear W25683031262022 @default.
- W2568303126 crossrefType "journal-article" @default.
- W2568303126 hasAuthorship W2568303126A5001428569 @default.
- W2568303126 hasAuthorship W2568303126A5002019310 @default.
- W2568303126 hasAuthorship W2568303126A5008127215 @default.
- W2568303126 hasAuthorship W2568303126A5008593691 @default.
- W2568303126 hasAuthorship W2568303126A5018757509 @default.
- W2568303126 hasAuthorship W2568303126A5019037704 @default.
- W2568303126 hasAuthorship W2568303126A5023055777 @default.
- W2568303126 hasAuthorship W2568303126A5025836672 @default.
- W2568303126 hasAuthorship W2568303126A5040129979 @default.
- W2568303126 hasAuthorship W2568303126A5040900859 @default.
- W2568303126 hasAuthorship W2568303126A5045508144 @default.
- W2568303126 hasAuthorship W2568303126A5047152744 @default.
- W2568303126 hasAuthorship W2568303126A5047402540 @default.
- W2568303126 hasAuthorship W2568303126A5049735686 @default.
- W2568303126 hasAuthorship W2568303126A5050112931 @default.
- W2568303126 hasAuthorship W2568303126A5055548058 @default.
- W2568303126 hasAuthorship W2568303126A5059355812 @default.
- W2568303126 hasAuthorship W2568303126A5060287300 @default.
- W2568303126 hasAuthorship W2568303126A5064697305 @default.
- W2568303126 hasAuthorship W2568303126A5079876695 @default.
- W2568303126 hasAuthorship W2568303126A5080195917 @default.
- W2568303126 hasBestOaLocation W25683031261 @default.
- W2568303126 hasConcept C121608353 @default.
- W2568303126 hasConcept C126322002 @default.
- W2568303126 hasConcept C141071460 @default.
- W2568303126 hasConcept C143998085 @default.
- W2568303126 hasConcept C2776694085 @default.
- W2568303126 hasConcept C2777701055 @default.
- W2568303126 hasConcept C2780057760 @default.
- W2568303126 hasConcept C2781190966 @default.
- W2568303126 hasConcept C71924100 @default.
- W2568303126 hasConceptScore W2568303126C121608353 @default.
- W2568303126 hasConceptScore W2568303126C126322002 @default.
- W2568303126 hasConceptScore W2568303126C141071460 @default.
- W2568303126 hasConceptScore W2568303126C143998085 @default.
- W2568303126 hasConceptScore W2568303126C2776694085 @default.
- W2568303126 hasConceptScore W2568303126C2777701055 @default.
- W2568303126 hasConceptScore W2568303126C2780057760 @default.
- W2568303126 hasConceptScore W2568303126C2781190966 @default.
- W2568303126 hasConceptScore W2568303126C71924100 @default.
- W2568303126 hasIssue "1" @default.
- W2568303126 hasLocation W25683031261 @default.
- W2568303126 hasOpenAccess W2568303126 @default.
- W2568303126 hasPrimaryLocation W25683031261 @default.
- W2568303126 hasRelatedWork W2080820783 @default.
- W2568303126 hasRelatedWork W2315587357 @default.
- W2568303126 hasRelatedWork W2476332031 @default.
- W2568303126 hasRelatedWork W2557996697 @default.
- W2568303126 hasRelatedWork W2743577629 @default.
- W2568303126 hasRelatedWork W2796582438 @default.
- W2568303126 hasRelatedWork W2811288290 @default.
- W2568303126 hasRelatedWork W3032029751 @default.
- W2568303126 hasRelatedWork W4254273398 @default.
- W2568303126 hasRelatedWork W4309266206 @default.
- W2568303126 hasVolume "12" @default.
- W2568303126 isParatext "false" @default.
- W2568303126 isRetracted "false" @default.
- W2568303126 magId "2568303126" @default.
- W2568303126 workType "article" @default.